^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NCL overexpression

i
Other names: NCL, Nucleolin, Nsr1, C23, Protein C23
Entrez ID:
1year
Light-Promoted Lysosomal Escape of a Phthalocyanine and Antisense Oligonucleotide-Complexed G-Quadruplex for Dual Photodynamic and Antisense Therapy. (PubMed, ACS Pharmacol Transl Sci)
It contains a nucleolin-targeting As1411-based G-quadruplex platform, a partially hybridized antisense oligonucleotide 4625, which can inhibit the antiapoptotic protein B cell lymphoma-xL inducing apoptotic cell death, and a zinc(II) phthalocyanine (ZnPc)-based photosensitizer held by noncovalent interactions...The combined therapeutic effect can eliminate the cancer cells effectively with a half maximal inhibitory concentration of ca. 0.5 μM.
Journal
|
NCL (Nucleolin)
|
NCL overexpression
|
QN-165
over1year
Innovative gelatin-based micelles with AS1411 aptamer targeting and reduction responsiveness for doxorubicin delivery in tumor therapy. (PubMed, Biomed Pharmacother)
It was revealed that AGSST-D micelles had no obvious systemic toxicity. Overall, AGSST micelles would have the potential to be an effective drug carrier for targeted tumor therapy.
Journal
|
NCL (Nucleolin)
|
NCL overexpression
|
doxorubicin hydrochloride • QN-165
almost2years
Construction of a Functional Nucleic Acid-Based Artificial Vesicle-Encapsulated Composite Nanoparticle and Its Application in Retinoblastoma-Targeted Theranostics. (PubMed, ACS Biomater Sci Eng)
Subsequently, the DNAzymes can target two different mRNAs, thereby realizing fluorescence/MR bimodal imaging and dual-gene therapy. This study is expected to provide a reliable and valuable basis for ocular tumor theranostics.
Journal
|
NCL (Nucleolin)
|
NCL overexpression
almost2years
Glowing Octopus-Inspired Nanomachine: A Versatile Aptasensor for Efficient Capture, Imaging, Separation, and NIR-Triggered Release of Cancer Cells. (PubMed, Anal Chem)
Employing magnet and NIR laser assistance enables easy separation and mild photothermal release of CTCs from the normal cells and the nanomachine without compromising cell viability. Moreover, the GOIN demonstrates a reusing capability, as the NIR-triggered CTC release is mild and nondestructive, allowing the GOIN to be reused at least three times.
Journal
|
NCL (Nucleolin)
|
NCL overexpression
2years
Dual-targeted delivery system using hollow silica nanoparticles with H-triggered bubble generating characteristic coated with hyaluronic acid and AS1411 for cancer therapy. (PubMed, Drug Dev Ind Pharm)
Herein, a dual-targeting delivery system using mesoporous silica nanoparticles with hollow structures (HMSNs) was developed for the specific delivery of epirubicin (EPI) to cancer cells and introducing a H-triggered bubble generating nanosystem (BGNS). The results of tumor inhibitory effect study exhibited that BGNS-EPI-HA-Apt complex decreased off-target effect and improved on-target effects because of its targeting ability. The data acquired substantiates that HA-surface modified HMSNs functionalized with aptamers possess significant potential as a focused platform for efficient transportation of anticancer agents to neoplastic tissues.
Journal
|
CD44 (CD44 Molecule) • NCL (Nucleolin)
|
NCL overexpression
|
epirubicin • QN-165
2years
Aptamer-modified tetrahedral DNA nanostructure-immobilized liposome for specific gene delivery and potential cancer theragnostic. (PubMed, Biotechnol J)
Furthermore, the co-delivery of mRNA and doxorubicin resulted in increased apoptosis and reduced cancer cell viability...Interestingly, co-delivery of mRNA and Dox did not show a significant difference in EGFP expression at 24 h but dramatically increased EGFP expression at 48 h, making ApTL/mEGFP/Dox a promising candidate for detecting live cancer cells after targeted cancer drug treatment. Our results suggest that ApTL can be a promising tool for the targeted delivery of therapeutic agents to nucleolin-overexpressing cancer cells, providing a new strategy for cancer theragnostic.
Journal • Epigenetic controller
|
NCL (Nucleolin)
|
NCL overexpression
|
doxorubicin hydrochloride
2years
Indomethacin Induces Spermidine/Spermine-N-Acetyltransferase-1 via the Nucleolin-CDK1 Axis and Synergizes with the Polyamine Oxidase Inhibitor Methoctramine in Lung Cancer Cells. (PubMed, Biomolecules)
We found that, when combined, indomethacin and methoctramine have a synergistic effect against NSCLC cells in vitro. These results suggest that indomethacin increases the SSAT-1 levels by reducing the CDK1-nucleolin regulatory axis, and the PAOX inhibition with methoctramine could improve the antiproliferative effect of indomethacin.
Journal
|
NCL (Nucleolin) • CDK1 (Cyclin-dependent kinase 1)
|
NCL overexpression
2years
Targeted delivery of doxorubicin and therapeutic FOXM1 aptamer to tumor cells using gold nanoparticles modified with AS1411 and ATP aptamers. (PubMed, Iran J Basic Med Sci)
The results confirmed that the targeted system improved the therapeutic effect by loading high amounts of Dox alongside the presence of the therapeutic effect of FOXM1 aptamer. Finally, it can be concluded that AuNPs-AFPA-Dox by enhancing antitumor effectiveness and reducing toxicity toward non-target cells, can be used potentially as an effective strategy for the treatment of breast cancer.
Journal • Tumor cell
|
FOXM1 (Forkhead Box M1) • NCL (Nucleolin)
|
NCL overexpression
|
doxorubicin hydrochloride • QN-165
over2years
Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). (PubMed, Int J Mol Med)
The AS1411 aptamers currently appear to have therapeutic action in the phase II clinical trial...The present review describes and discusses the mechanisms through which the multiple functions of NCL can participate in the progression of cancer. In addition, the studies that define the utility of NCL‑dependent anticancer therapies are summarized, with specific focus being paid to cancer immunotherapeutic approaches.
Review • Journal • IO biomarker
|
NCL (Nucleolin)
|
NCL overexpression
|
QN-165
over2years
Targeting nucleolin improves sensitivity to chemotherapy in acute lymphoblastic leukemia. (PubMed, Cell Oncol (Dordr))
Our results highlight NCL as a prognostic marker in B-ALL and a potential therapeutic target to combat chemotherapy resistance in ALL.
Journal
|
NCL (Nucleolin)
|
NCL overexpression
|
QN-165
over2years
RNA-binding domain 2 of nucleolin is important for the autophagy induction of curcumol in nasopharyngeal carcinoma cells. (PubMed, Phytomedicine)
The results demonstrated that NCL regulated cell autophagy was related with interaction of NCL and Akt in NPC cells. The expression of NCL play an important role in autophagy induction and further found that was associated with its effect on NCL RNA-binding domain 2. This study may provide a new perspective on the target protein studies for natural medicines and confirm the effect of curcumol not only regulating the expression of its target protein, but also influencing the function domain of its target protein.
Journal
|
NCL (Nucleolin)
|
NCL overexpression